ChromaDex Corporation (NASDAQ:CDXC) Q1 2023 Results Conference Call May 10, 2023 4:30 PM ET
Company Participants
Kendall Knysch - Director, Media Relations
Rob Fried - Chief Executive Officer
Brianna Gerber - Chief Financial Officer
Andrew Shao - Senior Vice President-Scientific and Regulatory Affairs
Conference Call Participants
Jeff Van Sinderen - B. Riley
Ram Selvaraju - H.C. Wainwright
Mitch Pinheiro - Sturdivant
Sean McGowan - ROTH MKM
JP Mark - Farmhouse Equity Research
Jeff Cohen - Ladenburg Thalmann
Matt Dhane - Tieton Capital Management
Operator
Ladies and gentlemen, thank you for standing by and welcome to ChromaDex Corporation's First Quarter 2023 Earnings Conference Call. My name is Brianna and I'll be the conference operator today. [Operator Instructions] And as a reminder, this conference call is being recorded.
This afternoon, ChromaDex issued a news release announcing the company’s financial results for the first quarter of 2023. If you have not reviewed this information, both are available within the Investor Relations section of ChromaDex’s website at www.chromadex.com.
I would now like to turn the conference call over to Kendall Knysch, Director of Media Relations. Please go ahead, Ms. Knysch.
Kendall Knysch
Good afternoon and welcome to ChromaDex Corporation's first quarter 2023 results investor call. With us today are ChromaDex's Chief Executive Officer, Rob Fried; Chief Financial Officer, Brianna Gerber; and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao, who will join the call for Q&A.
Today's conference call may include forward-looking statements, including statements related to ChromaDex's research and development and clinical trial plans and the timing and results of such trials, the timing of future regulatory filings, the expansion of the sale of Tru Niagen in new markets, business development opportunities, future financial results, cash needs, operating performance, investor interest and business prospects and opportunities, as well as anticipated results of operations.
Forward-looking statements represent only the company's estimates on the date of this conference call and are not intended to give any assurance as to actual future results. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties.
Many factors could cause ChromaDex's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These risk factors include those contained in ChromaDex's quarterly reports on Form 10-Q most recently filed with the SEC, including results of operations, financial condition, cash flows, the effect of the COVID-19 pandemic as well as inflationary and adverse economic conditions on our business.